On a consolidated basis, the companys revenue closed at Rs 3,053 crore while EBITDA margin stood at 15.1% which was an expansion of 202 bps versus Q1FY23-24.
Despite witnessing a late recovery in September, domestic pharma sales moderated sequentially in Q2, which is likely to put pressure on the July-September earnings of drugmakers
ICICI Securities posted strong quarterly numbers on all three major fronts of revenue, net profit and profitability. Along with that, the company also managed to gain market share across a few segments.
NIMs bottoming out, strong loan growth, network expansion and stable asset quality are some of the factors that favour India s biggest private sector lender